Ikarian Capital’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Ikarian Capital’s Portfolio MITO Stock Details MITO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-435,516	Closed	-$134K	–	124
2022 Q3	$134K	Sell	435,516 -66,320	-13%	-$18.9K	0.03%	97
2022 Q2	$127K	Hold	501,836	–	–	0.02%	128
2022 Q1	$350K	Buy	501,836 +23,275	+5%	+$15.7K	0.05%	151
2021 Q4	$397K	Hold	478,561	–	–	0.06%	139
2021 Q3	$651K	Sell	478,561 -9,453	-2%	-$12.8K	0.05%	177
2021 Q2	$761K	Sell	488,014 -300,000	-38%	-$419K	0.06%	170
2021 Q1	$1.24M	Buy	788,014 +750,417	+1,996%	+$1.29M	0.04%	230
2020 Q4	$57K	Hold	37,597	–	–	﹤0.01%	222
2020 Q3	$50K	Hold	37,597	–	–	﹤0.01%	169
2020 Q2	$69K	Hold	37,597	–	–	0.01%	159
2020 Q1	$47K	Hold	37,597	–	–	﹤0.01%	150
2019 Q4	$123K	Buy	+37,597	New	+$288K	0.02%	104

Ikarian Capital's MITO Position: Q4 2022 in Review

Ikarian Capital sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q4 2022, closing a stake of 435,516 shares — an estimated $134K sold.

Ikarian Capital first reported a position in MITO in Q4 2019 and held it in 12 quarters. The position peaked at $1.24M in Q1 2021. 0 funds tracked by Wall St. Rank hold MITO as of Q4 2022.

Ikarian Capital reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q4 2022 after selling out during the quarter.
Ikarian Capital sold 435,516 Stealth BioTherapeutics Corp. ADS shares in Q4 2022, an estimated $134K.
Ikarian Capital first reported a position in Stealth BioTherapeutics Corp. ADS in Q4 2019 and held it in 12 quarters.
Ikarian Capital's Stealth BioTherapeutics Corp. ADS position peaked at $1.24M in Q1 2021.
0 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q4 2022.

Based on Ikarian Capital's 13F filing for Q4 2022, filed 14 Feb 2023.